Open AccessEffective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector.
Author(s) -
René Bernards,
Antoinette Destree,
Sara McKenzie,
Ethel J. Gordon,
Robert A. Weinberg,
Dennis Panicali
Publication year - 1987
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.84.19.6854
Subject(s) - vaccinia , virology , recombinant dna , virus , oncogene , biology , poxviridae , antigen , recombinant virus , oncolytic virus , glycoprotein , cancer immunotherapy , transfection , antibody , immunization , 3t3 cells , immunotherapy , microbiology and biotechnology , cell culture , cancer , immune system , immunology , gene , cell cycle , genetics
We have constructed a vaccinia virus recombinant that expresses the extracellular domain of the rat neu oncogene-encoded protein, a 185-kDa transmembrane glycoprotein termed p185. Strain NFS mice immunized with this recombinant virus developed a strong antibody response against the neu oncogene product and were fully protected against subsequent tumor challenge with neu-transformed NIH 3T3 cells. No tumor immunoprotection was found when recombinant virus-immunized mice were challenged with Ha-ras-transformed NIH 3T3 cells. These data indicate that immunization with a single oncogene-encoded antigen can fully and specifically protect animals against tumor cells bearing this antigen.